IKBKG Antikörper (N-Term)

Produktnummer ABIN2779233

Produktdetails anti-IKBKG Antikörper

Target: IKBKG (Inhibitor of kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase gamma (IKBKG))

Bindungsspezifität: N-Term

Reaktivität: Human, Maus, Ratte, Kaninchen, Rind (Kuh), Hund, Meerschweinchen, Pferd, Schwein

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IKBKG Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Sequenz: MNRHLWKSQL CEMVQPSGGP AADQDVLGEE SPLGKPAMLH LPSEQGAPET

Homologie: Cow: 79%, Dog: 93%, Guinea Pig: 85%, Horse: 93%, Human: 100%, Mouse: 86%, Pig: 93%, Rabbit: 86%, Rat: 86%

Produktmerkmale: This is a rabbit polyclonal antibody against IKBKG. It was validated on Western Blot using a cell lysate as a positive control.

Aufreinigung: Affinity Purified

Immunogen: The immunogen is a synthetic peptide directed towards the N terminal region of human IKBKG

Anwendungsinformationen

Applikationshinweise: Optimal working dilutions should be determined experimentally by the investigator.

Kommentare:

Antigen size: 419 AA

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

Details zu IKBKG

Target: IKBKG (Inhibitor of kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase gamma (IKBKG))

Andere Bezeichnung: IKBKG (IKBKG Produkte)

Synonyme: AMCBX1 antikoerper, FIP-3 antikoerper, FIP3 antikoerper, Fip3p antikoerper, IKK-gamma antikoerper, IP antikoerper, IP1 antikoerper, IP2 antikoerper, IPD2 antikoerper, NEMO antikoerper, ZC2HC9 antikoerper, 1110037D23Rik antikoerper, AI848108 antikoerper, AI851264 antikoerper, AW124339 antikoerper, IKK[g] antikoerper, Nemo antikoerper, nemo antikoerper, fj33c07 antikoerper, wu:fj33c07 antikoerper, zgc:113492 antikoerper, MGC97885 antikoerper, IKBKG antikoerper, IKBKG_1 antikoerper, IKBKG_2 antikoerper, CG16910 antikoerper, DmIKK-gamma antikoerper, DmIKKgamma antikoerper, Dmel\\CG16910 antikoerper, Dmikkgamma antikoerper, IKK antikoerper, IKK[[gamma]] antikoerper, IKKg antikoerper, IKKgamma antikoerper, KEY antikoerper, Kenny antikoerper, Key antikoerper, dIKK antikoerper, dIKK-gamma antikoerper, dmIKKgamma antikoerper, inhibitor of nuclear factor kappa B kinase subunit gamma antikoerper, inhibitor of kappaB kinase gamma antikoerper, inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma antikoerper, inhibitor of nuclear factor kappa B kinase subunit gamma L homeolog antikoerper, kenny antikoerper, IKBKG antikoerper, Ikbkg antikoerper, ikbkg antikoerper, ikbkg.L antikoerper, IKBKG_1 antikoerper, key antikoerper

Hintergrund: IKBKG is the regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. IKBKG also considered to be a mediator for TAX activation of NF-kappa-B. IKBKG could be implicated in NF-kappa-B-mediated protection from cytokine toxicity.Familial incontinentia pigmenti (IP) is a genodermatosis that segregates as an X-linked dominant disorder and is usually lethal prenatally in males (The International Incontinentia Pigmenti Consortium, 2000 [PubMed 10839543]). In affected females it causes highly variable abnormalities of the skin, hair, nails, teeth, eyes, and central nervous system. The prominent skin signs occur in 4 classic cutaneous stages: perinatal inflammatory vesicles, verrucous patches, a distinctive pattern of hyperpigmentation, and dermal scarring. Cells expressing the mutated X chromosome are eliminated selectively around the time of birth, so females with IP exhibit extremely skewed X-inactivation. Familial incontinentia pigmenti is caused by mutations in the NEMO gene and is here referred to as IP2, or 'classical' incontinentia pigmenti. Sporadic incontinentia pigmenti, the so-called IP1, which maps to Xp11, is categorized as hypomelanosis of Ito (MIM 300337).[supplied by OMIM]. Sequence Note: removed 1 base from the 5' end that did not align to the reference genome assembly. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications. PRIMARYREFSEQ_SPAN PRIMARY_IDENTIFIER PRIMARY_SPAN COMP 1-2120 AF261086.1 2-2121
Alias Symbols: AMCBX1, FIP-3, FIP3, Fip3p, IKK-gamma, IP, IP1, IP2, IPD2, NEMO
Protein Interaction Partner: CHUK, IKBKB, ATM, PIAS4, MALT1, TRIM13, BCL10, SUMO1, UBC, TRAF6, MTOR, RPTOR, RELA, NFKBIA, IKBKG, ARHGDIA, RHOA, CDC37, SRC, FYN, FKBP5, FGR, PPP4C, PPP2R1B, LYN, NMRAL1, USP7, ZC3H12A, IRAK1, USP10, RIPK1, SQSTM1, RNF31, PPP1CC, HDLBP, PPFIA1, PSMB8, K
Protein Size: 419

Molekulargewicht: 48 kDa

Gen-ID: 8517

NCBI Accession: NM_003639, NP_003630

UniProt: Q9Y6K9

Pathways: NF-kappaB Signalweg, RTK Signalweg, T-Zell Rezeptor Signalweg, TLR Signalweg, Fc-epsilon Rezeptor Signalübertragung, Activation of Innate immune Response, M Phase, Production of Molecular Mediator of Immune Response, Hepatitis C, Protein targeting to Nucleus, Toll-Like Receptors Cascades, BCR Signaling, Ubiquitin Proteasome Pathway, S100 Proteine